Literature DB >> 30181091

GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community.

T Cederholm1, G L Jensen2, M I T D Correia3, M C Gonzalez4, R Fukushima5, T Higashiguchi6, G Baptista7, R Barazzoni8, R Blaauw9, A Coats10, A Crivelli11, D C Evans12, L Gramlich13, V Fuchs-Tarlovsky14, H Keller15, L Llido16, A Malone17, K M Mogensen18, J E Morley19, M Muscaritoli20, I Nyulasi21, M Pirlich22, V Pisprasert23, M A E de van der Schueren24, S Siltharm25, P Singer26, K Tappenden27, N Velasco28, D Waitzberg29, P Yamwong30, J Yu31, A Van Gossum32, C Compher33.   

Abstract

RATIONALE: This initiative is focused on building a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings.
METHODS: In January 2016, the Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. GLIM appointed a core leadership committee and a supporting working group with representatives bringing additional global diversity and expertise. Empirical consensus was reached through a series of face-to-face meetings, telephone conferences, and e-mail communications.
RESULTS: A two-step approach for the malnutrition diagnosis was selected, i.e., first screening to identify "at risk" status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among the GLIM core and supporting working group members. The top five ranked criteria included three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present. Phenotypic metrics for grading severity as Stage 1 (moderate) and Stage 2 (severe) malnutrition are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology-related diagnosis categories.
CONCLUSION: A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure further collaboration and endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The diagnostic construct should be re-considered every 3-5 years.
Copyright © 2018 Elsevier Ltd, European Society for Clinical Nutrition and Metabolism and American Society for Parenteral and Enteral Nutrition. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Assessment; Diagnosis; Malnutrition; Screening

Mesh:

Year:  2018        PMID: 30181091     DOI: 10.1016/j.clnu.2018.08.002

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  260 in total

Review 1.  Under-Recognizing Malnutrition in Hospitalized Obese Populations: The Real Paradox.

Authors:  Kavita Sharma; Kris M Mogensen; Malcolm K Robinson
Journal:  Curr Nutr Rep       Date:  2019-12

2.  Reply to Wakabayashi Regarding "Sarcopenia is an Independent Risk Factor for Dysphagia in Community-Dwelling Older Adults".

Authors:  Seungwoo Cha; Won-Seok Kim; Nam-Jong Paik
Journal:  Dysphagia       Date:  2019-03-11       Impact factor: 3.438

3.  Editorial: Screening for the Anorexia of Aging.

Authors:  C Warne; I T Forrester; L Jones; J E Morley
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

4.  Multidisciplinary nutritional consensus on assessment and nutritional dietary treatment in patients with chronic kidney disease and SARS-CoV-2 infection.

Authors:  Almudena Pérez-Torres; Alberto Caverni Muñoz; Luis Miguel Lou Arnal; Alejandro Sanz Paris; Concepción Vidal Peracho; Juan la Torre Catalá; Rafael Sánchez Villanueva; Secundino Cigarrán Guldris; Filomeno Trocoli González; Ángel Nogueira Pérez; Ana Sanjurjo Amado; M Elena González García; Guillermina Barril Cuadrado
Journal:  Nefrologia (Engl Ed)       Date:  2021-01-28

Review 5.  Multidomain Frailty in Heart Failure: Current Status and Future Perspectives.

Authors:  Shinya Tanaka; Masashi Yamashita; Hiroshi Saito; Kentaro Kamiya; Daichi Maeda; Masaaki Konishi; Yuya Matsue
Journal:  Curr Heart Fail Rep       Date:  2021-04-09

6.  Comment on "Sarcopenia is an Independent Risk Factor for Dysphagia in Community-Dwelling Older Adults".

Authors:  Hidetaka Wakabayashi
Journal:  Dysphagia       Date:  2019-01-30       Impact factor: 3.438

7.  Patient and carer experiences of nutrition in cancer care: a mixed-methods study.

Authors:  Jenelle Loeliger; Sarah Dewar; Nicole Kiss; Allison Drosdowsky; Jane Stewart
Journal:  Support Care Cancer       Date:  2021-03-12       Impact factor: 3.603

8.  Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5-year in the SarcoPhAge cohort.

Authors:  Laetitia Lengelé; Olivier Bruyère; Charlotte Beaudart; Jean-Yves Reginster; Médéa Locquet
Journal:  Aging Clin Exp Res       Date:  2021-05-15       Impact factor: 3.636

9.  Joint action malnutrition in the elderly (MaNuEL) knowledge hub: summary of project findings.

Authors:  D Volkert; M Visser; C A Corish; C Geisler; L de Groot; A J Cruz-Jentoft; C Lohrmann; E M O'Connor; K Schindler; M A E de van der Schueren
Journal:  Eur Geriatr Med       Date:  2019-11-20       Impact factor: 1.710

10.  Prevalence of malnutrition in systemic sclerosis patients assessed by different diagnostic tools.

Authors:  Anna Wojteczek; Jolanta A Dardzińska; Sylwia Małgorzewicz; Agnieszka Gruszecka; Zbigniew Zdrojewski
Journal:  Clin Rheumatol       Date:  2019-11-16       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.